Figure 1

Strategy I: Using shorter PEG segment

Strategy II: Loading multiple drug molecules on each COOH groups

Figure 2





Figure 3 Lactone Ring Stability of CPT, 11 and 12 in PBS (pH 7.4)



5

Figure 4




Figure 5a: Polymerization control by adjusting polymerization time.




Figure 5b: Polymerization control by adjusting polymerization time.




Figure 6: CPT release from **HG6** and **HGGG6** at 37 °C after 24 h in buffer solutions with pHs ranging from 1.1 to 13.1




Figure 7: HPLC analysis of degradation of CD-BisCys-SS-Peg3400 Polymer




Figure 8. The tumor growth curve as a function of time for the D5W, CPT, irinotecan, LGGG10 at its highest non-toxic dose tested (18 mg CPT/kg), and the other three conjugates with high MW polymer (HGGG6, HG6, HGGG10) at their MTDs.




Fig. 9. The median tumor growth curves for HGGG6, HG6 and HGGG10





Figure 10: The medium tumor growth curves for LGGG10 and HGGG10 each dosed at 9 mg CPT/kg



5

Figure 11: Mean body weight (MBW) losses as a function of time plotted for D5W, CPT, irinotecan and the three conjugates containing high MW polymer at their MTDs





Figure 12. The correlation of CPT concentration (ng/mg tissue) to tumor size (in mg)



5